Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
Identifieur interne : 000052 ( Canada/Analysis ); précédent : 000051; suivant : 000053Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
Auteurs : R. Sadovsky [États-Unis] ; G. B. Brock [Canada] ; S. W. Gutkin [États-Unis] ; S. Sorsaburu [États-Unis]Source :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2009-08.
Abstract
Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well‐being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first‐line therapies for men with ED. To help physicians maximise the likelihood of treatment success with these agents, we conducted an English‐language PubMed search of articles involving approved PDE5 inhibitors dating from 1 January 1998 (the year in which sildenafil citrate was introduced), through 31 August 2008. In addition to sildenafil, tadalafil and vardenafil, search terms included ‘adhere*’, ‘couple*’, ‘effect*’, ‘effic*’, ‘partner*’, ‘satisf*’, ‘succe*’ and ‘treatment outcome.’ Based on our analysis, physician activities to promote favourable treatment outcomes may be captured under the mnemonic ‘EPOCH’: (i) Evaluating and educating patients and partners to ensure realistic expectations of therapy; (ii) Prescribing a treatment individualised to the couple’s lifestyle needs and other preferences; (iii) Optimising treatment outcomes by scheduling follow‐up visits with the patient to ‘fine‐tune’ dosages and revisit key educational messages; (iv) Controlling comorbidities via lifestyle counselling, medications and/or referrals and (v) Helping patients and their partners to meet their health and psychosocial needs, potentially referring them to a specialist for other forms of therapy if they are not satisfied with PDE5 inhibitors.
Url:
DOI: 10.1111/j.1742-1241.2009.02119.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001486
- to stream Istex, to step Curation: 001483
- to stream Istex, to step Checkpoint: 000236
- to stream Main, to step Merge: 000453
- to stream Main, to step Curation: 000454
- to stream Main, to step Exploration: 000454
- to stream Canada, to step Extraction: 000052
Links to Exploration step
ISTEX:B70B5F5F2FC820E085E82E338E241E8F790F36BBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction</title><author><name sortKey="Sadovsky, R" sort="Sadovsky, R" uniqKey="Sadovsky R" first="R." last="Sadovsky">R. Sadovsky</name></author><author><name sortKey="Brock, G B" sort="Brock, G B" uniqKey="Brock G" first="G. B." last="Brock">G. B. Brock</name></author><author><name sortKey="Gutkin, S W" sort="Gutkin, S W" uniqKey="Gutkin S" first="S. W." last="Gutkin">S. W. Gutkin</name></author><author><name sortKey="Sorsaburu, S" sort="Sorsaburu, S" uniqKey="Sorsaburu S" first="S." last="Sorsaburu">S. Sorsaburu</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B70B5F5F2FC820E085E82E338E241E8F790F36BB</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1742-1241.2009.02119.x</idno><idno type="url">https://api.istex.fr/document/B70B5F5F2FC820E085E82E338E241E8F790F36BB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001486</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001486</idno><idno type="wicri:Area/Istex/Curation">001483</idno><idno type="wicri:Area/Istex/Checkpoint">000236</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000236</idno><idno type="wicri:doubleKey">1368-5031:2009:Sadovsky R:toward:a:new</idno><idno type="wicri:Area/Main/Merge">000453</idno><idno type="wicri:Area/Main/Curation">000454</idno><idno type="wicri:Area/Main/Exploration">000454</idno><idno type="wicri:Area/Canada/Extraction">000052</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction</title><author><name sortKey="Sadovsky, R" sort="Sadovsky, R" uniqKey="Sadovsky R" first="R." last="Sadovsky">R. Sadovsky</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>State University of New York, Downstate Medical Center, Brooklyn, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Brock, G B" sort="Brock, G B" uniqKey="Brock G" first="G. B." last="Brock">G. B. Brock</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Urology, Faculty of Medicine and Dentistry, University of Western Ontario, London, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Gutkin, S W" sort="Gutkin, S W" uniqKey="Gutkin S" first="S. W." last="Gutkin">S. W. Gutkin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rete Biomedical Communications Corp., Wyckoff, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Sorsaburu, S" sort="Sorsaburu, S" uniqKey="Sorsaburu S" first="S." last="Sorsaburu">S. Sorsaburu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Eli Lilly and Company, Indianapolis, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Clinical Practice</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-08">2009-08</date><biblScope unit="volume">63</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1214">1214</biblScope><biblScope unit="page" to="1230">1230</biblScope></imprint><idno type="ISSN">1368-5031</idno></series><idno type="istex">B70B5F5F2FC820E085E82E338E241E8F790F36BB</idno><idno type="DOI">10.1111/j.1742-1241.2009.02119.x</idno><idno type="ArticleID">IJCP2119</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well‐being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first‐line therapies for men with ED. To help physicians maximise the likelihood of treatment success with these agents, we conducted an English‐language PubMed search of articles involving approved PDE5 inhibitors dating from 1 January 1998 (the year in which sildenafil citrate was introduced), through 31 August 2008. In addition to sildenafil, tadalafil and vardenafil, search terms included ‘adhere*’, ‘couple*’, ‘effect*’, ‘effic*’, ‘partner*’, ‘satisf*’, ‘succe*’ and ‘treatment outcome.’ Based on our analysis, physician activities to promote favourable treatment outcomes may be captured under the mnemonic ‘EPOCH’: (i) Evaluating and educating patients and partners to ensure realistic expectations of therapy; (ii) Prescribing a treatment individualised to the couple’s lifestyle needs and other preferences; (iii) Optimising treatment outcomes by scheduling follow‐up visits with the patient to ‘fine‐tune’ dosages and revisit key educational messages; (iv) Controlling comorbidities via lifestyle counselling, medications and/or referrals and (v) Helping patients and their partners to meet their health and psychosocial needs, potentially referring them to a specialist for other forms of therapy if they are not satisfied with PDE5 inhibitors.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Indiana</li><li>New Jersey</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Sadovsky, R" sort="Sadovsky, R" uniqKey="Sadovsky R" first="R." last="Sadovsky">R. Sadovsky</name></region><name sortKey="Gutkin, S W" sort="Gutkin, S W" uniqKey="Gutkin S" first="S. W." last="Gutkin">S. W. Gutkin</name><name sortKey="Sorsaburu, S" sort="Sorsaburu, S" uniqKey="Sorsaburu S" first="S." last="Sorsaburu">S. Sorsaburu</name></country><country name="Canada"><noRegion><name sortKey="Brock, G B" sort="Brock, G B" uniqKey="Brock G" first="G. B." last="Brock">G. B. Brock</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/TherFamFrancoV1/Data/Canada/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000052 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd -nk 000052 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= TherFamFrancoV1
|flux= Canada
|étape= Analysis
|type= RBID
|clé= ISTEX:B70B5F5F2FC820E085E82E338E241E8F790F36BB
|texte= Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
}}
| This area was generated with Dilib version V0.6.29. |  |